In biopharma, success goes beyond innovation—it's about strategic collaboration. With development costs hitting $2.3 billion and approval rates below 4%, the stakes are high. As new therapies emerge and patents expire, navigating challenges requires expert partners who can help pave the way from lab to patient. https://ow.ly/RXjP50U8EnX
Cencora | Pharma solutions
制药业
Conshohocken，PA 31,638 位关注者
At Cencora, we are investing and innovating alongside our pharma customers to unlock their product’s potential.
关于我们
At Cencora, we are investing and innovating alongside our pharma customers to unlock their product’s potential. Cencora is a leading global pharmaceutical solutions organization centered on improving lives. We partner with pharmaceutical innovators and care providers to facilitate access to pharmaceuticals and healthcare products. Our pharma solutions — ranging from support during drug discovery to lifecycle management — help pharmaceutical and biopharma companies of all sizes reach full product potential. Previously known as AmerisourceBergen, our 46,000+ Cencora team members power our purpose: We are united in our responsibility to create healthier futures.?Cencora is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500 with more than $200 billion in annual revenue. Learn more at www.Cencora.com.?
- 网站
-
https://www.amerisourcebergen.com/manufacturer-solutions/contact-us?utm_source=linkedIn&utm_medium=socialmedia&utm_campaign=gps_012_bps_linkedin_showcase&utm_content=contact-us-button
Cencora | Pharma solutions的外部链接
- 所属行业
- 制药业
- 规模
- 超过 10,001 人
- 总部
- Conshohocken，PA
- 类型
- 上市公司
- 领域
- patient services、market access、distribution、global consulting、field solutions、RWE generation、HEOR、Pharmacovigilance、regulatory affairs、QMC、logicistics、promotional materials、pharma和pharma commercialization
地点
-
主要
获取路线
US，PA，Conshohocken，19428
Cencora | Pharma solutions员工
动态
-
Serving our customers is one of our highest priorities. Recently, team members from our Consumer Products team stepped up in an urgent situation to support a mother and her child in delivering a device they desperately needed. Read the story: https://ow.ly/9SWT50TsxlM
-
-
Payer denials can keep your therapies from patients. Watch the video to see how a key team addition can relieve frustration and improve patient access. Watch full video: https://ow.ly/PEhH50U2FUE
-
?? We are excited to share that the Verband Forschender Arzneimittelhersteller e.V. (VFA) has released a new press release emphasizing the need to better utilize Germany’s participation quotas in clinical trials. ?This initiative, in cooperation with Vintura and the Cencora | Pharma solutions RWE team, aims to enhance the country’s role in global medical research and ensure that more patients can benefit from cutting-edge treatments. ??Let’s work together to advance medical research and improve healthcare outcomes! If you want to further dive into this topic, feel free to contact Jan-Philipp Beck or Ann-Sophie Kuschel from Vintura. #ClinicalTrials #MedicalResearch #Healthcare #Innovation
???Publikation einer partnerschaftlichen Kooperation best?tigt klar: Eine Studienteilnahme hat messbare Vorteile und nützt Patient*innen, ?rzteschaft und auch dem Gesundheitswesen in Deutschland!??? Nach einer intensiven Zusammenarbeit zwischen acht Mitgliedsunternehmen unseres Verbandes und der Partner-Agentur Vintura freuen wir uns, die Ver?ffentlichung unserer Publikation zum Thema Studiennutzen bekannt zu geben:?"Evaluating Patient Participation in Clinical Trials for #CLL and #SLE in Germany—A Mixed-Methods Study on Enrollment Potential Based on Claims Data". Die Ergebnisse sind besonders relevant für: ?? Patient*innen, die über eine Studienteilnahme frühzeitigen Zugang zu innovativen Therapien erhalten? ?? ?rzteschaft, die sich im Rahmen von Studien früher mit neuen Behandlungsoptionen auseinandersetzen.? ?? Gesundheitssystem, das durch Studien zus?tzliche Ressourcen und St?rkung Deutschlands als Innovationsstandort erf?hrt Unsere Auswertung zeigt, dass es ein ungenutztes Potenzial gibt, Patient*innen v.a. mit chronischen Krankheiten in klinische Studien einzubeziehen. Der weitere Ausbau klinischer Studien und der breite Nutzen einer Studienteilnahme sind entscheidend, um Deutschland als Innovationszentrum zu st?rken und den Patient*innen zeitnahen Zugang zu medizinischen Innovationen zu erm?glichen. Wir wünschen eine erkenntnisreiche Lektüre der vollst?ndigen Studie (der Link findet sich in den Kommentaren). Zu den Krankheiten: CLL: Die chronische lymphatische Leuk?mie ist eine Krebserkrankung des lymphatischen Systems und meist auch des Blutes und in Deutschland die h?ufigste Blutkrebs-Erkrankung bei Erwachsenen. Zum lymphatischen System geh?ren unter anderem Lymphknoten, Milz und Knochenmark. SLE: Der systemische Lupus Erythematodes ist eine Autoimmunerkrankung. Es kommt zum Angriff des Immunsystem auf k?rpereigene gesunde Zellen. Die Folge sind Entzündungsreaktion und Organsch?den. Amgen Deutschland AstraZeneca Bristol Myers Squibb Bayer | Pharmaceuticals Boehringer Ingelheim Lilly Deutschland GmbH Novartis Deutschland Roche Deutschland #Pharma #KlinischeStudien #Innovation #Gesundheit #Deutschland #Patientenversorgung #Forschung?
-
-
Emily Whitehead’s story inspired a global movement in cell and gene therapy. Diagnosed with acute lymphoblastic leukemia (ALL) at age five and after exhausting standard treatments, Emily was the first pediatric patient in the world to receive CAR-T therapy in 2012. Since her treatment, more than 34,000 cancer patients have received CAR-T therapies. George Eastwood, the Emily Whitehead Foundation's Board Chair and Interim Executive Director, joined us at Cencora’s ThinkLive Cell and Gene Therapy Summit. Watch the session and learn more about the critical role of early diagnosis, patient engagement, and support in advancing therapies ?? https://ow.ly/KJ5k50U8Eg4
-
-
It was a packed house for Cencora's ISPOR Europe 2024 presentation: Ready for 2025? How Lessons Learned From National System Reforms Can Guide Our Response to the New EU HTA Regulations Focusing on the upcoming joint clinical assessment (JCA) and its impact on the European healthcare industry, Herbert Altmann, PhD led an expert panel that explored key reforms in Germany, Spain, France, and Poland, and discussed strategies for accelerating patient access to innovative medicines. Key takeaways included: ??Fresh insights into HTA process reforms and their impact on healthcare access, innovation, and pricing ??Strategies to align national systems with EU regulations for smooth implementation ??How national reforms can serve as blueprints for improving patient outcomes Visit our ISPOR Europe event page to learn more: https://lnkd.in/ezQVcyhm #HealthcareInnovation #JCA #PatientAccess #HTAReforms #Pharma #EURegulations #ISPOREurope
-
-
I’m excited to be speaking at #AccessEU ‘24 on November 16, right before #ISPOREU I'll be sharing insights on USA Market Access along with global experts from the EU and China. I'll dive into: ?? An overview of the US healthcare system, including private and public payers. ?? Unique pricing and market access strategies in the US. ?? The implications of the Inflation Reduction Act. ?? The crucial but limited role of the FDA in drug approvals and patient access. ?? Tackling access challenges and lessons learned. We are looking forward to discussing how different healthcare systems around the world approach market access, and what valuable insights can we gain from each other ???? If you are attending AccessEU, let’s connect! If not, would still love to hear your perspective. #Healthcare #AccessForum #MarketAccess #PatientAccess ?#Innovation #AccessEU #ISPOREU
-
-
There are several ways to unlock AI’s capabilities and potential. Hear from key experts as they highlight trends to watch and discuss future opportunities to accelerate the trajectory of AI in evidence generation strategies. Watch the webinar: https://ow.ly/4wHQ50TZNlh
-
-
Heading to ISPOR Europe 2024 in Barcelona? We are incredibly proud to unveil groundbreaking research at the conference and participate in discussions on the latest advancements in Health Economics and Outcomes Research (HEOR). Explore our conference program to hear from our experts as they share their findings. We've planned unique experiences to welcome visitors, clients, and colleagues as we celebrate key milestones together. From HEOR and real-world evidence to market access, European HTA, and digital innovation, our team will be available to answer all your questions! And don’t forget to join our morning run on Monday to kick off the conference with energy! Visit our event page: https://lnkd.in/ezQVcyhm #ISPOREurope #EUHTA #PatientAccess #MarketAccess